Patents Assigned to Pieris AG
  • Publication number: 20160280747
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. A like immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Application
    Filed: April 6, 2016
    Publication date: September 29, 2016
    Applicant: Pieris AG
    Inventors: ARNE SKERRA, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Publication number: 20160256525
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Application
    Filed: December 28, 2015
    Publication date: September 8, 2016
    Applicant: Pieris AG
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Patent number: 9260492
    Abstract: Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 16, 2016
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Kristian Jensen
  • Patent number: 9221885
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: December 29, 2015
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
  • Patent number: 9221887
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 29, 2015
    Assignee: Pieris AG
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Patent number: 9212208
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: December 15, 2015
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
  • Patent number: 8986951
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: March 24, 2015
    Assignee: Pieris AG
    Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
  • Publication number: 20140288008
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicants: Daiichi Sankyo Company, Limited, Pieris AG
    Inventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
  • Publication number: 20140080177
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Application
    Filed: August 20, 2013
    Publication date: March 20, 2014
    Applicant: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Patent number: 8536307
    Abstract: The invention relates to the production of novel proteins exhibiting binding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using genetic engineering methods. Like immunoglobulin, the anticalin thus obtained can be used to identify or bind molecular structures.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: September 17, 2013
    Assignee: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Patent number: 8313924
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: November 20, 2012
    Assignee: Pieris AG
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Patent number: 8158753
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: April 17, 2012
    Assignee: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Patent number: 7892827
    Abstract: The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid.
    Type: Grant
    Filed: November 25, 2005
    Date of Patent: February 22, 2011
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Steffen Schlehuber, Martin Pöhlchen, Arne Skerra
  • Patent number: 7893208
    Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: February 22, 2011
    Assignee: Pieris AG
    Inventors: Arne Skerra, Steffen Schlehuber
  • Patent number: 7723476
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: May 25, 2010
    Assignee: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Patent number: 7691970
    Abstract: The present invention relates to novel muteins derived from a bilin-binding protein (BBP) that binds a given target, for example a macromolecular target, with detectable affinity. In particular, the invention relates to a mutein of the bilin-binding protein of Pieris brassicae. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: April 6, 2010
    Assignee: Pieris AG
    Inventors: Arne Skerra, Steffen Schlehuber
  • Patent number: 7585940
    Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.
    Type: Grant
    Filed: August 24, 2004
    Date of Patent: September 8, 2009
    Assignee: Pieris AG
    Inventors: Arne Skerra, Steffen Schlehuber
  • Patent number: 7252998
    Abstract: Disclosed is a method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat ?2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target. The method comprises the step of subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in one or more mutein(s) of the protein. Also disclosed are muteins obtainable by this method.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: August 7, 2007
    Assignee: Pieris AG
    Inventors: Arne Skerra, Steffen Schlehuber
  • Patent number: 7250297
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using genetic engineering methods. A like immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: July 31, 2007
    Assignee: Pieris AG
    Inventors: Gerald Beste, Thomas Stibora, Arne Skerre, Frank Schmidt